SKOKIE, Ill. – January 5, 2021 – World-renowned litigators Steven Cherny and Ray Nimrod join the advisory board of Azul 3D.
Leading experts in patent and technology-related litigation, Cherny and Nimrod are both partners at Quinn Emanuel Urquhart & Sullivan. They have long worked in the field of innovation, helping companies solve the complex issues that arise when bringing new technology to market.
Cherny and Nimrod cite their confidence in Azul 3D cofounder Chad A. Mirkin and the 3D-printing startup’s record-breaking high-area rapid printing (HARP™) platform as motivations for joining the board.
“As an intellectual property lawyer in the field of innovation, I have become very familiar with the 3D-printing field,” Cherny said. “When I first learned about Azul 3D, I immediately recognized that it was different from its competitors. Its signature HARP innovation is unmatched, and I knew I wanted to be a part of working with this incredible technology.”
“3D printing has become an important tool for the manufacturing industry, and it’s clear that Azul 3D is poised to lead this increasingly crucial field,” Nimrod added. “HARP is the only 3D-printing technology with the speed and throughput to not just transform printing but all of manufacturing. I look forward to working with the entire Azul team, in their efforts to develop and expand the scope of this ground-breaking technology.”
“We are thrilled to have Steve and Ray as both investors and board members,” said Dr. David Walker, Azul3D’s chief technology officer. “Going forward, their expertise will help establish our IP strategy and broaden the footprint of Azul’s already impressive intellectual property estate.”
A lecturer at the University of Chicago, Cherny has twice been named Litigator of the Week by “The American Lawyer.” He has tried some of the largest patent cases before the federal courts and International Trade Commission. This includes Bard v. Gore, which resulted in one of the largest civil judgements ever collected, and Innovatio v. Cisco, a pioneering case in the area of identifying and valuing standards essential patents.
The chair of Quinn Emanuel’s biotech litigation practice, Nimrod was recognized as Life Science General Patent Litigator of the Year in New York by LMG Life Sciences. He also serves as lead litigation counsel for the firm’s technology clients, including Dow Chemical, Johnson & Johnson, Merck, Mitsubishi Tanabe, Cree, Vifor, Fresenius and Harvard and MIT’s Broad Institute. He has tried dozens of patent cases, collecting billions of dollars for his clients on the plaintiff side as well as representing clients on the defense side in bet-the-company patent infringement cases. Among his current representations, Nimrod serves as lead counsel for the Broad Institute in litigation relating to CRISPR gene editing technology, which was described by Fortune as “the biotech fight of the century.”
ABOUT AZUL 3D™
Azul 3D™ is a leading-edge 3D printing company that is transforming the additive manufacturing industry. Initially invented and developed at Northwestern University, HARP™ allows one to print 3D structures from a wide pallet of materials. The initial printers based upon HARP™ are capable of manufacturing parts at production speeds, regardless of size, with a throughput dramatically outpacing its competitors and becoming competitive with injection molding. Azul 3D™ is enabling manufacturers to transition from prototype to mass-manufacturing on a single, streamlined production platform. In combination with its proprietary industrial-grade materials, it offers the opportunity for just-in-time mass production of diverse, highly customized products.